Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2017 | T-cell lymphoma: autologous or allogeneic transplant?

Francine Foss, MD, from the Yale University School of Medicine, New Haven, CT, discusses the role of transplantation in T-cell lymphoma at the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2017 meeting, held in Vancouver, BC, Canada. The current NCCN guidelines recommend autologous transplantation for patients with aggressive T-cell lymphoma, however, it is not clearly defined which patients will benefit from this treatment. Approximately 60% of patients who receive an autologous transplant progress within 5 years. It needs to be determined if there is a role for maintenance therapy after autologous transplant, to improve this response rate. The role of allogeneic transplant must also be further explored as a potentially curative modality. This video was supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) through an unrestricted educational grant to Magdalen Medical Publishing. The company had no influence on the production of this content.